Healixa Inc. announces that Christopher Galliano will join its Board of Directors as a non-executive independent Director effective January 11, 2022, demonstrating the company's focus on corporate governance, growth and national list requirements. Mr. Galliano currently serves as Chief Technology Officer and Co-Founder of Skymount Medical, where he co-authored over 6 patents in artificial intelligence based drug discovery and leads the day to day research to construct an oral therapeutic for COVID-19 and 12 other active inventions/pharmaceutical developments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0799 USD | -19.70% | -20.10% | -71.46% |
1st Jan change | Capi. | |
---|---|---|
-71.46% | 70.86M | |
+12.51% | 3,096B | |
+12.68% | 85.37B | |
+7.61% | 77.1B | |
-13.71% | 54.31B | |
-22.56% | 47.92B | |
+26.21% | 47.74B | |
+25.42% | 42.15B | |
+69.48% | 38.06B | |
-8.00% | 24.73B |
- Stock Market
- Equities
- EMOR Stock
- News Healixa Inc.
- Healixa, Inc. Appoints Christopher Galliano as Independent Director to its Board